Edwards Lifesciences (NYSE:EW) Issues Q3 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its third quarter 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 0.710-0.770 for the period, compared to the consensus earnings per share estimate of 0.740. The company issued revenue guidance of $1.6 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Edwards Lifesciences also updated its FY 2026 guidance to 2.950-3.050 EPS.

Edwards Lifesciences Stock Down 0.9%

Shares of NYSE:EW traded down $0.74 on Thursday, hitting $83.63. 6,726,014 shares of the company traded hands, compared to its average volume of 4,876,617. Edwards Lifesciences has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The stock has a 50 day simple moving average of $87.65 and a 200-day simple moving average of $83.90. The company has a market cap of $48.15 billion, a PE ratio of 44.48, a PEG ratio of 2.12 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts expect that Edwards Lifesciences will post 3 earnings per share for the current year.

Analyst Ratings Changes

EW has been the topic of several analyst reports. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Mizuho boosted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Truist Financial upped their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Citigroup lifted their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $98.95.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $83.01, for a total transaction of $84,587.19. Following the completion of the sale, the vice president owned 33,934 shares of the company’s stock, valued at $2,816,861.34. This represents a 2.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 45,577 shares of company stock valued at $3,855,527. Insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $25,000. Kemnay Advisory Services Inc. purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $27,000. Rakuten Securities Inc. lifted its position in shares of Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 302 shares in the last quarter. Kelleher Financial Advisors bought a new position in shares of Edwards Lifesciences in the third quarter worth about $50,000. Finally, Chapman Financial Group LLC purchased a new stake in shares of Edwards Lifesciences during the second quarter worth about $63,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.